Literature DB >> 10658677

Characteristic expression of Hck in human B-cell precursors.

T Taguchi1, N Kiyokawa, N Sato, M Saito, J Fujimoto.   

Abstract

OBJECTIVE: To identify molecules involved in signaling for early B-cell development, we investigated the expression of signal transduction-related proteins in B-cell progenitors.
MATERIALS AND METHODS: [corrected] Normal as well as leukemic B-cell progenitors were examined by immunoblotting and immunofluorescence study.
RESULTS: [corrected] In a survey of the expression of a broad range of signal transduction molecules, the Src-family protein tyrosine kinases were found to be differentially expressed in early B-cell differentiation. [corrected] Analysis of freshly prepared precursor-B acute lymphoblastic leukemia cells and B-lineage cell lines showed Hck and Lyn are major Src-family protein tyrosine kinases expressed in this type of leukemic blasts. [corrected] However, heterogeneity of Hck and Lyn expression was found in these cells, and precursor-B acute lymphoblastic leukemia cells subsequently were classified according to the expression pattern of Hck and Lyn as Hck/Lyn dual-negative, Hck-predominant, Hck/Lyn dual-positive, and Lyn-predominant. Further studies on normal B-lineage cells indicated that the Src-family protein tyrosine kinases are expressed sequentially in a differentiation-dependent fashion during B-cell ontogeny and that the predominant expression of Hck is a common feature in B-cell progenitors, whereas Lyn expression is more significant in mature B cells.
CONCLUSIONS: Although the biologic significance remains unknown, sequential expression of Src-family protein tyrosine kinases should play a role in regulation of early B-cell differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10658677     DOI: 10.1016/s0301-472x(99)00127-7

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  6 in total

1.  Involvement of the HCK and FGR src-family kinases in FCRL4-mediated immune regulation.

Authors:  Yanling Liu; Ksenia Bezverbnaya; Tiantian Zhao; Marion J Parsons; Mengyao Shi; Bebhinn Treanor; Götz R A Ehrhardt
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

Review 2.  Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Authors:  Valerie I Brown; Alix E Seif; Gregor S D Reid; David T Teachey; Stephan A Grupp
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.

Authors:  Xia Liu; Jiaji G Chen; Manit Munshi; Zachary R Hunter; Lian Xu; Amanda Kofides; Nickolas Tsakmaklis; Maria G Demos; Maria Luisa Guerrera; Gloria G Chan; Cristina Jimenez; Christopher J Patterson; Kirsten Meid; Andrew Keezer; Jorge J Castillo; Steven P Treon; Guang Yang
Journal:  Blood Adv       Date:  2020-01-14

Review 4.  Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia.

Authors:  Justin F Creeden; Khaled Alganem; Ali S Imami; Nicholas D Henkel; F Charles Brunicardi; Shi-He Liu; Rammohan Shukla; Tushar Tomar; Faris Naji; Robert E McCullumsmith
Journal:  Int J Mol Sci       Date:  2020-11-21       Impact factor: 5.923

5.  A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.

Authors:  Manit Munshi; Xia Liu; Amanda Kofides; Nickolas Tsakmaklis; Maria Luisa Guerrera; Zachary R Hunter; M Lia Palomba; Kimon V Argyropoulos; Christopher J Patterson; Alexa G Canning; Kirsten Meid; Joshua Gustine; Andrew R Branagan; Catherine A Flynn; Shayna Sarosiek; Jorge J Castillo; Jinhua Wang; Sara J Buhrlage; Nathanael S Gray; Nikhil C Munshi; Kenneth C Anderson; Steven P Treon; Guang Yang
Journal:  Blood Adv       Date:  2022-06-14

6.  The class-specific BCR tonic signal modulates lymphomagenesis in a c-myc deregulation transgenic model.

Authors:  Rada Amin; Abdelghafour Marfak; Céline Pangault; Christelle Oblet; Aurélie Chanut; Karin Tarte; Yves Denizot; Michel Cogné
Journal:  Oncotarget       Date:  2014-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.